Annual report pursuant to Section 13 and 15(d)

Revenue - Narrative (Details)

v3.19.1
Revenue - Narrative (Details)
€ in Millions
 1 Months Ended 12 Months Ended
Feb. 08, 2018
USD ($)
swap_option
research_program
unit_of_accounting
license
May 02, 2017
USD ($)
unit_of_accounting
Feb. 27, 2017
USD ($)
Jan. 04, 2017
product
Jan. 04, 2017
EUR (€)
product
Jan. 04, 2017
USD ($)
product
Jan. 04, 2017
research_program
product
Jan. 04, 2017
bispecific_therapeutic_program
product
Jan. 04, 2017
extension_option
product
Jan. 04, 2017
unit_of_accounting
product
Jan. 04, 2017
product
license
Feb. 28, 2019
EUR (€)
Feb. 28, 2019
USD ($)
Dec. 31, 2018
EUR (€)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Disaggregation of Revenue [Line Items]                                  
Upfront license payment                               $ 26,677,000 $ 11,285,000
Research and development services                               1,762,000 1,403,000
Milestone payments                               571,000 12,573,000
Current deferred revenue                             $ 35,612,000 35,612,000 37,153,000
Non-current deferred revenue                             53,303,000 53,303,000 46,542,000
Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Remaining performance obligation                             0 0  
AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term   5 years                              
Milestone payments                                 12,600,000
Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Remaining performance obligation                             0 0  
Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term       3 years                          
ASKA Pharmaceutical Co. Ltd.                                  
Disaggregation of Revenue [Line Items]                                  
Deferred revenue                             2,940,000 2,940,000  
Evaluation period     60 days                            
License and Collaboration Agreement | Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Period after effective date agreements may be terminated 12 months                                
Contract termination advance notice period 90 days                                
Agreement termination advance notice period if marketing approval obtained 180 days                                
Agreement termination notice period upon material breach by the Company 90 days                                
Contract termination due to material breach, additional notice period if the breach is not susceptible 90 days                                
Number of licenses | license 3                                
Number of swap options | swap_option 2                                
Number of units of accounting | unit_of_accounting 6                                
Number of research programs | research_program 3                                
License and Collaboration Agreement | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Period after effective date agreements may be terminated   12 months                              
Contract termination advance notice period   90 days                              
Agreement termination advance notice period if marketing approval obtained   180 days                              
Agreement termination notice period upon material breach by the Company   180 days                              
Agreement termination notice period upon breach of payment obligations by the Company   30 days                              
Contract termination due to material breach, additional notice period if the breach is not susceptible   180 days                              
Number of units of accounting | unit_of_accounting   11                              
License and Collaboration Agreement | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Number of licenses | license                     5            
Number of units of accounting | unit_of_accounting                   10              
Number of research programs             3 5                  
Sales Milestones | Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Current deferred revenue                             4,600,000 4,600,000  
Non-current deferred revenue                             18,500,000 18,500,000  
Sales Milestones | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Current deferred revenue                             25,500,000 25,500,000  
Non-current deferred revenue                             6,800,000 6,800,000  
Sales Milestones | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Deferred revenue                             2,600,000 2,600,000  
Non-current deferred revenue                             28,000,000 28,000,000  
Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Period after effective date agreements may be terminated       12 months                          
Contract termination advance notice period       180 days                          
Milestone payments                           € 0.5 $ 600,000    
Number of collaboration products | product       4 4 4 4 4 4 4 4            
Number of worldwide collaboration products | product       2 2 2 2 2 2 2 2            
Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier | Subsequent Event                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments                       € 1.5 $ 1,700,000        
Strategic Partnerships and Other License Agreements | ASKA Pharmaceutical Co. Ltd.                                  
Disaggregation of Revenue [Line Items]                                  
Agreement termination notice period upon breach of payment obligations by the Company     30 days                            
Milestone payments                               $ 0 $ 0
Upfront Payment | Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Upfront license payment $ 30,000,000                                
Research and development services 4,900,000                                
Deferred revenue 1,200,000,000                                
Allocable arrangement consideration $ 34,900,000                                
Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   $ 45,000,000                              
Upfront Payment | ASKA Pharmaceutical Co. Ltd.                                  
Disaggregation of Revenue [Line Items]                                  
Upfront option payment received     $ 2,750,000                            
Upfront Payment | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Upfront license payment         € 30.0 $ 32,000,000                      
Estimated Development and Manufacturing Services | Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   8,200,000                              
Relative Selling Price Method | Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   53,200,000                              
Extension Term | Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term       1 year                          
Number of agreement extension options | extension_option                 2                
Minimum | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term       2 years                          
Minimum | Substantive Development and Sales Milestone | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments   72,200,000                              
Minimum | Non-Substantive Development and Sales Milestones | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments   366,200,000                              
Minimum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Agreement termination notice period upon material breach by the Company       90 days                          
Maximum | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term       3 years                          
Maximum | Substantive Development and Sales Milestone | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments   611,400,000                              
Maximum | Substantive Development and Sales Milestone | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments | €         € 163.0                        
Maximum | Non-Substantive Development and Sales Milestones | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments   1,100,000,000                              
Maximum | Sales Milestones | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Milestone payments   $ 1,000,000,000                              
Maximum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Agreement termination notice period upon material breach by the Company       120 days